1887

Abstract

Introduction:

Antibiotic‐associated diarrhoea (AAD) is one of the most common side effects of antibiotic therapy. The main mechanism associated with the development of AAD is significant changes in the composition and quantity of the gut microbiota during the treatment with antibiotics. Probiotic bacteria have been shown to stabilize the gut microbiota and can be used to prevent diarrhoea associated with antibiotic therapy.

Case presentation:

We present the results of a single‐centre, randomized, double‐blinded, placebo‐controlled clinical trial. Patients were randomized into three groups: probiotic group 1 received a probiotic containing strains 3 and 31; probiotic group 2 received a probiotic, containing 3; and the placebo group received an inert composition in vials, formulated to be indistinguishable from the vials with probiotics. Participants received one vial twice a day. Probiotic treatment significantly reduced incidents of AAD in the patients. Among 91 patients in group 1 treated with probiotic mix, nine developed AAD. In group 2, seven patients out of 90 who received only one probiotic strain developed AAD. A considerably higher incidence of AAD was registered in the placebo group – 23 from 90 patients (<0.001 vs groups 1 and 2). Both probiotics demonstrated a significant effect in the prevention of nausea, bloating, vomiting and abdominal pain.

Conclusion:

Treatment with probiotics during antibiotic therapy significantly decreased the incidence of AAD and adverse effects related to the use of antibiotics. Both probiotics were well tolerated by the patients without side effects. No significant difference was found in the efficacy of the two probiotics

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.004036
2014-09-01
2019-09-15
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/1/3/jmmcr004036.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.004036&mimeType=html&fmt=ahah

References

  1. Bartlett J.G. . ( 2002; ). Antibiotic‐associated diarrhea. . N Engl J Med 346:, 334–339.[CrossRef]
    [Google Scholar]
  2. Canani R.B. , Cirillo P. , Terrin G. , Cesarano L. , Spagnuolo M.I. , de Vincenzo A. , Albano F. , Passariello A. , de Marco G. . other authors ( 2007; ). Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. . Br Med J 335:, 340.[CrossRef]
    [Google Scholar]
  3. Coppi F. , Ruoppolo M. , Mandressi A. , Bellorofonte C. , Gonnella G. , Trinchieri A. . ( 1985; ). Results of treatment with Bacillus subtilis spores (Enterogermina) after antibiotic therapy in 95 patients with infection calculosis. . Chemioterapia 4:, 467–470.
    [Google Scholar]
  4. Dolin B.J. . ( 2009; ). Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea‐predominant irritable bowel syndrome. . Methods Find Exp Clin Pharmacol 31:, 655–659.[CrossRef]
    [Google Scholar]
  5. Friedman G. . ( 2012; ). The role of probiotics in the prevention and treatment of antibiotic‐associated diarrhea and Clostridium difficile colitis. . Gastroenterol Clin North Am 41:, 763–779.[CrossRef]
    [Google Scholar]
  6. Fujiya M. , Musch M.W. , Nakagawa Y. , Hu S. , Alverdy J. , Kohgo Y. , Schneewind O. , Jabri B. , Chang E.B. . ( 2007; ). The Bacillus subtilis quorum‐sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. . Cell Host Microbe 1:, 299–308.[CrossRef]
    [Google Scholar]
  7. Gao X.W. , Mubasher M. , Fang C.Y. , Reifer C. , Miller L.E. . ( 2010; ). Dose–response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic‐associated diarrhea and Clostridium difficile‐associated diarrhea prophylaxis in adult patients. . Am J of Gastroenterol 105:, 1636–1641.[CrossRef]
    [Google Scholar]
  8. Gorkiewicz G. . ( 2009; ). Nosocomial and antibiotic‐associated diarrhoea caused by organisms other than Clostridium difficile . . Int J Antimicrob Agents 33:, S37–S41.[CrossRef]
    [Google Scholar]
  9. Gracheva N.M. , Gavrilov A.F. , Solov’eva A.I. , Smirnov V.V. , Sorokulova I.B. , Reznik S.R. , Chudnovskaia N.V. . ( 1996; ). The efficacy of the new bacterial preparation biosporin in treating acute intestinal infections. . Zh Mikrobiol Epidemiol Immunobiol 75–77.
    [Google Scholar]
  10. Hun L. . ( 2009; ). Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. . Postgrad Med 121:, 119–124.[CrossRef]
    [Google Scholar]
  11. Kalman D.S. , Schwartz H.I. , Alvarez P. , Feldman S. , Pezzullo J.C. , Krieger D.R. . ( 2009; ). A prospective, randomized, double‐blind, placebo‐controlled parallel‐group dual site trial to evaluate the effects of a Bacillus coagulans‐based product on functional intestinal gas symptoms. . BMC Gastroenterol 9:, 85.[CrossRef]
    [Google Scholar]
  12. Mazza P. . ( 1994; ). The use of Bacillus subtilis as antidiarrhoeal microorganism. . Boll Chim Farm 133:, 3–18.
    [Google Scholar]
  13. Nista E.C. , Candelli M. , Cremonini F. , Cazzato I.A. , Zocco M.A. , Franceschi F. , Cammarota G. , Gasbarrini G. , Gasbarrini A. . ( 2004; ). Bacillus clausii therapy to reduce side‐effects of anti‐Helicobacter pylori treatment: randomized, double‐blind, placebo controlled trial. . Aliment Pharmacol Ther 20:, 1181–1188.[CrossRef]
    [Google Scholar]
  14. Persborn M. , Gerritsen J. , Wallon C. , Carlsson A. , Akkermans L.M.A. , Soderholm J.D. . ( 2013; ). The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. . Aliment Pharmacol Ther 38:, 772–783.[CrossRef]
    [Google Scholar]
  15. Pinchuk I.V. , Bressollier P. , Verneuil B. , Fenet B. , Sorokulova I.B. , Megraud F. , Urdaci M.C. . ( 2001; ). In vitro anti‐Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. . Antimicrob Agents Chemother 45:, 3156–61.[CrossRef]
    [Google Scholar]
  16. Sorokulova I. . ( 2008; ). Preclinical testing in the development of probiotics: a regulatory perspective with Bacillus strains as an example. . Clin Infect Dis 46:, S92–S95.[CrossRef]
    [Google Scholar]
  17. Sorokulova I.B. , Kirik D.L. , Pinchuk I.V. . ( 1997; ). Probiotics against Campylobacter pathogens. . J Travel Med 4:, 167–170.[CrossRef]
    [Google Scholar]
  18. Sorokulova I.B. , Safronova L.A. , Vinogradov V.N. , Tyshkevich V.N. , Hilko T.V. , Starenkaya S.Y. , Lapa S.V. . ( 2003; ). Correction of intestinal microflora disturbances in newborn infants with Biosporin. . Perinatologiya ta pediatria 2:, 23–26.
    [Google Scholar]
  19. Sorokulova I.B. , Pinchuk I.V. , Denayrolles M. , Osipova I.G. , Huang J.M. , Cutting S.M. , Urdaci M.C. . ( 2008; ). The safety of two Bacillus probiotic strains for human use. . Dig Dis Sci 53:, 954–963.[CrossRef]
    [Google Scholar]
  20. Wistrom J. , Norrby S.R. , Myhre E.B. , Eriksson S. , Granstrom G. , Lagergren L. , Englund G. , Nord C.E. , Svenungsson B. . ( 2001; ). Frequency of antibiotic‐associated diarrhoea in 2462 antibiotic‐treated hospitalized patients: a prospective study. . Journal of Antimicrobial Chemotherapy 47:, 43–50.[CrossRef]
    [Google Scholar]
  21. Young V.B. , Schmidt T.M. . ( 2004; ). Antibiotic‐associated diarrhea accompanied by large‐scale alterations in the composition of the fecal microbiota. . J Clin Microbiol 42:, 1203–1206.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.004036
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.004036
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error